期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤肾脏切除在转移性肾细胞癌治疗中的意义 被引量：1

The role of cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma
下载PDF
导出
摘要 转移性肾细胞癌的治疗是肾癌治疗的难点。以往认为转移性肾细胞癌切除肿瘤原发灶是没有意义的。但随着肾癌免疫治疗和靶向治疗的发展,越来越多的证据证明肿瘤肾脏切除在转移性肾细胞癌的治疗中有着重要意义。本文通过复习相关文献对肿瘤肾脏切除术在转移性肾细胞癌治疗中的意义作简单介绍。 The therapy of metastatic renal cell carcinoma was complicated. Former studies indicated that cytoreductive ne- phrectomy was not useful. But with the development of immunotherapy and target therapy,more and more evidence came up to convince the role of cytoreductive nephrectomy in treatment. We reviewed in this paper the literature on cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma.
作者 潘铁军 周宇
机构地区 广州军区武汉总医院泌尿外科
出处 《现代泌尿外科杂志》 CAS 2014年第2期80-82,共3页 Journal of Modern Urology
关键词 转移性肾细胞癌 肿瘤肾脏切除术 靶向治疗 免疫治疗 保留肾单位手术 metastatic renal cell carcinoma cytoreductive nephrectomy target therapy immunotherapy nephron spare surgery
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1HOFFMAN NE,GILLET MD,CHEVILLE JC. Difference in organ system of distant metastses by mRCC subtypes[J].{H}Journal Of Urology,2008.474-477.
  • 2DEKERNION JB,RAMMING KP,SMITH RB. The natural history of mRCC:A computer analysis[J].{H}Journal Of Urology,1978.148-152.
  • 3RINI BI,CAMPBELL SC. The evolving role of surgery for advanced renal cancer in the era of molecular targeted therapy[J].{H}Journal Of Urology,2007.1978-1984.
  • 4FLANIGAN RC,SALMON SE,BLUMENSTIEN BA. Nephrectomy followed by IFN alfa compared with IFN alfa alone for metastatic renal cell cancer[J].{H}New England Journal of Medicine,2001.1655-1661.
  • 5MICKISCH GH,GARIN A,VON POPPEL H. Radical nephrectomy plus IFN alfa based immunotherapy compared to IFN alone in metastatic renal cell cancer:A randomized trial[J].{H}LANCET,2001.966-970.
  • 6FLANIGAN RC,MICKISCH G,SYLVESTOR R. Cytoreductive nephrectomy in patients with metastatic renal cell cancer:A combined analysis[J].{H}Journal Of Urology,2004.1071-1076.
  • 7KASSOUF W,SANCHEZ ORTEZ R,TAMBOLI P. Cytoreductive nephrectomy for mRCC with non clear histology[J].{H}Journal Of Urology,2007.1896-1900.
  • 8WALTHER MM,ALEXANDER RB,WEISS GH. Cytoreductive nephrectomy before high dose IL2 based therapy in patients with metastatic RCC[J].{H}UROLOGY,1993.250-254.
  • 9THOMAS AA,RINI BI,LANE BR. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell cancer[J].{H}Journal Of Urology,2009.518-524.
  • 10RACKLEY RR,NOVICK AC,KLIEN EA. The impact of ad junctive nephrectomy on multimodality treatment of metastatic renal cellcancer[J].{H}Journal Of Urology,1994.1399-1403.

同被引文献16

  • 1HOUEIRI TK, ATKINS MB. Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit? [J]. Nat Rev Clin Oncol, 2009,6 (12) : 679-680.
  • 2KUME H,KAKUTANI S, Y YAMADA, et al. Prognostic fac tors for renal ceil carcinoma with bone metastasis: who are the long-term survivors? [J]. J Urol, 2011,185(5) :1611-1614.
  • 3EISEN T, AHMAD T, FLAHERTY KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis[J]. Br J Cancer,2006,95(5) :581.
  • 4BLUMENSCHEIN GR JR, GATZEMEIER U, FOSSELLA F, et al. Phase 1] , multicenter, uncontrolled trial of single agent sorafenib in patients with relapsed or refractory, advanced non small cell lung cancer[J]. J Clin Oneol, 2009,27 (26) : 4274-4280.
  • 5ESCUDIER B, EISEN T, STADI.ER WM, et al. Sorafenib in advanced clear cell renal-cell carcinoma[J]. N Engl J Mad, 2007, 356.,125-134.
  • 6PROCOPIO G, BELLMUNT J, DUTCHER J, et al. Sorafenih tolerability in elderly patients with advanced Renal cell carcino- ma: results from a large pooled analysis[J]. Br J Cancer,2013, 108(2) :311-318.
  • 7KIM SP, MURAD MH, THOMPSON RH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and mata-analysis[J]. J Urol, 2012,188(1) : 51-57.
  • 8STRUMBERG D. Preclinical and clinical development of the oral muhikinase in hibitor sorafenib in cancer treatment [J]. Drugs Today(Bare) ,2005,41(12) : 773-784.
  • 9WILHELM SM, CARTER C, TANG L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved jn tumor progression and angiogenesis[J]. Cancer Res, 2004,64(19) : 7099-7109.
  • 10PAWEL DE BINSKI, JANUSZ DEMBOWSKI, PAWEL KOW- AL, et al. The clinical significance of lymphangiogenesis in renal cell carcinoma[J]. Med Sei Monit, 2013,19(1):606-611.

引证文献1

二级引证文献5

现代泌尿外科杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部